Catalyst Pharmaceutical Inc.

Catalyst Pharmaceutical's RSI of 73.3 signals extreme overbought territory, yet the stock trades at a reasonable 17.78 P/E relative to pharmaceutical peers. With an $3.8B market cap and only 8.89% short interest, there's minimal squeeze catalyst. The current positioning suggests the stock has already priced in considerable optimism—the steep RSI combined with modest valuation multiples creates tension between momentum strength and fundamental value. The absence of significant short positioning removes a potential tailwind, while the overbought reading indicates limited room for continued upside without a consolidation or pullback. This setup favors caution for those considering entry points.